Valuation : Curis, Inc.

Market Cap 2.97M 2.56M 2.41M 2.19M 4.13M 282M 4.15M 28.47M 11.08M 143M 11.14M 10.9M 475M P/E 2026 *
-0.06x
P/E 2027 * -0.2x
Enterprise Value 2.97M 2.56M 2.41M 2.19M 4.13M 282M 4.15M 28.47M 11.08M 143M 11.14M 10.9M 475M EV / Sales 2026 *
-
EV / Sales 2027 * 0.32x
Free-Float
93.55%
Yield 2026 *
-
Yield 2027 * -

Last Transcript : Curis, Inc.

1 day-0.70%
1 week-8.44%
Current month-5.37%
1 month-72.62%
3 months-85.97%
6 months-93.47%
Current year-92.86%
1 week 1.4
Extreme 1.4
1.59
1 month 1.4
Extreme 1.4
5.5
Current year 1.4
Extreme 1.4
24.2
1 year 1.4
Extreme 1.4
39
3 years 1.4
Extreme 1.4
349.8
5 years 1.4
Extreme 1.4
3,492
10 years 1.4
Extreme 1.4
7,440
Manager TitleAgeSince
Chief Executive Officer 59 24/09/2018
Director of Finance/CFO 54 05/08/2022
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 73 01/11/2003
Chairman 84 16/05/2017
Director/Board Member 71 03/06/2010
Date Insider Type Main position Quantity % Market Cap. Importance
07/07/26 Free

Chief Executive Officer

110,090 0.2824%
07/07/26 Free

Director

6,800 0.0174%
07/07/26 Free

Chairman

6,800 0.0174%
Change 5-day change 1-year change 3-year change Capi.($)
-0.70%-8.44%-95.70%-99.37% 2.97M
+1.89%-0.61%+3.66%+17.95% 49.74B
+0.12%-0.71%+452.73%+498.77% 44.98B
+1.17%-1.15%+40.69%+17.03% 42.52B
+2.93%-2.69%+10.13%+78.52% 40.78B
-0.48%-0.84%+16.25%+49.80% 32.89B
+2.29%+4.45% - - 17.09B
+1.09%-6.02%+22.91%+119.46% 16.28B
+1.76%0.00%+18.60%+28.16% 14.4B
+1.21%-5.14%+72.89%+34.69% 13.48B
Average +1.25%-3.27%+60.24%+82.78% 27.22B
Weighted average by Cap. +1.40%-2.27%+97.41%+124.32%

Financials

2026 *2027 *
Net sales - 9.25M 7.98M 7.51M 6.84M 12.86M 878M 12.93M 88.73M 34.54M 447M 34.73M 33.98M 1.48B
Net income -52.02M -44.87M -42.21M -38.45M -72.31M -4.94B -72.7M -499M -194M -2.51B -195M -191M -8.33B -45.23M -39.02M -36.7M -33.44M -62.87M -4.29B -63.21M -434M -169M -2.18B -170M -166M -7.24B
Net Debt - -
Logo Curis, Inc.
Curis, Inc. is a biotechnology company. The Company is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). The Erivedge, is a commercialized orally administered small molecule Hedgehog signaling pathway antagonist. Its other clinical programs include Fimepinostat and CA-170. CA-170 is an oral small molecule drug candidate that targets V-domain Ig Suppressor of T-cell Activation, or VISTA, and PDL1 immune checkpoint proteins.
Employees
22
Date Price Change Volume
02/09/26 $1.410 -0.70% 4,446
01/09/26 $1.420 -4.70% 65,423
31/08/26 $1.490 0.00% 35,842
28/08/26 $1.490 -0.67% 119,833
27/08/26 $1.500 -2.60% 288,289
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.420USD
Average target price
42.67USD
Spread / Average Target
+2,904.70%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CRIS Stock